Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
about
Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectivesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsProton-associated sucrose transport of mammalian solute carrier family 45: an analysis in Saccharomyces cerevisiaePathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humansMobilization and removing of cadmium from kidney by GMDTC utilizing renal glucose reabsorption pathwayNovel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesSelective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitusTofogliflozin: first global approval.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialA mathematical model of the rat nephron: glucose transport.LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Novel Agents for the Treatment of Type 2 Diabetes.SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.Empagliflozin for the treatment of Type 2 diabetes.Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.Recent advances in glucose-lowering treatment to reduce diabetic kidney disease.Combined HQSAR, topomer CoMFA, homology modeling and docking studies on triazole derivatives as SGLT2 inhibitors.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis.A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humansDevelopment of a microphysiological model of human kidney proximal tubule function.Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.
P2860
Q26767263-D9270E11-BA0F-4CB5-B5FD-743CFBD4DFE8Q28072765-2CFAE3EB-32ED-4C53-AEC2-54E3CB4BF632Q28595094-386643B7-2E59-4723-B542-E4C1715F32E7Q30597265-A8B7B326-8E38-4D96-8AFD-D10514183D80Q33356608-177048F3-28FA-4FE8-B97E-701355110F9EQ33594514-B9788DCA-1E38-40F2-B1C0-D9B05C78F1DBQ33771405-F5649E21-B689-4ECA-8037-A298ED6C2AB6Q34198692-F6B4A873-2844-4A9C-852E-489192D87631Q34318349-9956C03C-AB0D-4A68-B71C-C575A66FBAF8Q34407893-D4AAB688-136B-4FFA-8ABC-0A5D00846629Q34420901-6758A780-E0AE-4058-A730-A41FAB127B26Q34804900-E7FA52E9-B737-4A20-A571-0ACD46F17DDCQ35622486-CABB74C7-FCF3-48BD-9FD7-80A882547D39Q35664940-9A6C22B5-BF6F-41A0-A3AB-E9C641651898Q35831426-D265939A-D430-4025-9BED-CD2A21804CA5Q35906490-56B2F29F-1B0B-47BD-A33B-5864AF544C39Q35910421-F34D26A4-946B-40F5-BB8D-665067AA5ED6Q36372598-6BB1803D-8C89-4CE3-B6B2-3229EDC5DF54Q37193454-0A3CF468-2875-4572-8EAF-5DA11851931CQ37524302-0E212F0E-0084-4C65-82E7-31E6FE716640Q37575461-B66FE164-381F-4472-B43B-E9EA49BF29CCQ38085691-C073DB9D-E39D-4097-8458-32B77315EB81Q38104746-7606BE82-1107-4207-AD83-82831A69D68CQ38130748-CA85E4B9-DBF5-4399-B4B4-39CDFD98484FQ38151450-57A8EC92-4477-4E22-A872-BC97AA44B4BFQ38176145-809B132E-9806-44E1-8BE6-488F022F53B9Q38203327-AE9955BC-A3CA-4156-8B04-66AD1EFA7104Q38340949-8D384429-5687-4165-A3E3-C1EF9303C95DQ38442040-06D86BF0-42F8-4166-97E7-9589103D9E18Q38668657-B4B94AD7-52A0-4772-B09D-D8CFEBFA2BB0Q38796262-3E533600-738C-468D-BCCB-D52CD155CE5BQ38800979-F5DF1527-0BDD-40B8-AA79-B7F35837B940Q38908779-B5B1671B-0C61-4644-BBA1-E8D4132F0FB0Q38936746-B1D78377-69C7-4929-9900-4A5FAFB77CB7Q39189383-98C75B90-C69C-48F7-9899-B6634F898B93Q39355218-645AE112-2CA6-41DC-900B-EB375EDBBB13Q41020576-E0EF96BE-CDC6-44FF-9D24-559DD64F4D4BQ41649918-26B998BA-1964-4E35-96A4-1BC80DF70A72Q41728004-76734808-9354-4F28-A0D6-514872520B3FQ41922447-6527656A-2551-4A68-B324-B511EAA075DF
P2860
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
@ast
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
@en
type
label
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
@ast
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
@en
prefLabel
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
@ast
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
@en
P2860
P356
P1433
P1476
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
@en
P2093
Jiwen Jim Liu
TaeWeon Lee
P2860
P304
P356
10.2337/DB12-0052
P407
P577
2012-09-01T00:00:00Z